101. Development of a risk prediction model for subsequent infection after colonization with carbapenem-resistant Enterobacterales: a retrospective cohort study
- Author
-
Guanhao Zheng, Jiaqi Cai, Han Deng, Haoyu Yang, Wenling Xiong, Hao Bai, and Juan He
- Abstract
Background Colonization of carbapenem-resistant Enterobacterale (CRE) is considered as one of vital preconditions for infection, with corresponding high morbidity and mortality. It is indispensable to construct a reliable prediction model and develop preventive and therapeutic strategies for those high-risk infected CRE carriers. Methods A retrospective cohort study was conducted in two Chinese tertiary hospitals for patients with CRE colonization from 2011 to 2021. Univariate analysis and the Fine-Gray subdistribution hazard model were utilized to identify potential risk factors for CRE-colonized infection, while death was the competing event. A nomogram was established to predict 30-day and 60-day risk of CRE-colonized infection. Results 879 eligible patients were enrolled in our study and divided into training (n = 761) and validation (n = 118) group, respectively. There were 196 (25.8%) patients suffered from subsequent CRE infection within 20 (interquartile range [IQR], 14–32) days after detection of colonization. Multisite colonization, polymicrobial colonization, catheterization and receiving albumin after colonization, concomitant respiratory diseases, receiving carbapenems and antimicrobial combination therapy before CRE colonization within 90 days were reserved in final model. Model discrimination and calibration were acceptable for predicting the probability of 60-day CRE-colonized infection in both training (area under the curve [AUC], 74.7) and validation dataset (AUC, 81.1). Decision-curve analysis revealed a significantly better net benefit in current model. Our prediction model is freely available online at https://ken-zheng.shinyapps.io/PredictingModelofCREcolonizedInfection/. Conclusions Our nomogram has a favorable predictive performance, which is deemed as a meaningful clinical tool for early identification of CRE carriers in high-risk status of subsequent infection.
- Published
- 2023